2009至2021年德国WHO 2级和3级胶质瘤的流行病学
本研究基于德国Robert Koch研究所癌症登记数据,分析2009至2021年组织学诊断的WHO 2级和3级胶质瘤真实世界流行病学,并结合文献综述与德国低级别胶质瘤疾病登记数据,将结果置于WHO 2021分类背景下。新诊断胶质瘤中仅9.0%和9.2%分别为2级和3级,发病率保持稳定;文献显示WHO 2021前标准下2级和3级胶质瘤IDH突变率分别约86%和60%。
要点
- 新诊断胶质瘤中2级和3级分别占9.0%和9.2%,多数为4级。
- 观察期内2级和3级胶质瘤发病率保持稳定。
- 文献估计2级和3级胶质瘤IDH突变率分别约86%和60%。
核心结论
- 本研究概述了德国人群中WHO 2级和3级胶质瘤的发病率。
- 本研究强调需将分子信息整合进胶质瘤流行病学监测,以获得对生存和预后因素更精确的洞察。
研究设计与样本
- 利用德国Robert Koch研究所癌症登记中心数据,纳入2009至2021年组织学新诊断的2级和3级胶质瘤,为总计14,053例胶质瘤病例(包括高级别胶质瘤)的子集。
- 补充探索性文献综述关于IDH突变率和德国低级别胶质瘤疾病登记(LoG-Glio)的流行病学数据。
主要发现
- 新诊断胶质瘤的肿瘤分类分布显示多数为4级胶质瘤,仅9.0%和9.2%分别为2级或3级。
- 观察期内发病率保持稳定。
- 文献数据表明,按WHO 2021前标准诊断的2级和3级胶质瘤中IDH突变率分别约86%和60%。
- 将上述比例应用于2009至2021年平均发病例数,估计IDH突变2级胶质瘤459例和3级胶质瘤328例(星形细胞瘤和少突胶质细胞瘤合并),德国新诊断IDH突变胶质瘤发病率分别为每10万人口0.6和0.5。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study provides a comprehensive analysis of the real-world epidemiology of histologically assessed IDH-mutated or IDH-wildtype grade II and III gliomas in Germany between 2009 and 2021, supplemented with a literature-based approach of setting the data in the context of the WHO 2021 classification. METHODS: Data from the Centre for Cancer Registry Data (ZfKD) at the Robert Koch-Institute (RKI) was utilized, encompassing all incident cases of histologically (according to the WHO classification of the respective time) newly diagnosed grade II and III gliomas diagnosed between 2009 and 2021, representing a subgroup of the total number of 14,053 glioma cases (including high grade glioma). Data were supplemented with an exploratory literature review on IDH-mutation rates and epidemiology data from the German low-grade glioma (LoG-Glio) disease registry. RESULTS: The tumor class distribution of newly diagnosed gliomas showed the majority being classified as grade IV glioma and only 9.0% and 9.2% as grade II or III, respectively. The incidence remained stable over the observation period. Literature data indicate mutation rates of IDH of approximately 86% in grade II and 60% in grade III gliomas diagnosed using pre-WHO-2021 criteria. Applying these proportions to 2009-2021 mean incidence cases numbers in an estimate of 459 grade 2 and 328 grade 3 IDH-mutated gliomas (combining astrocytoma and oligodendroglioma) and an incidence rate of 0.6 and 0.5 per 100.000 population for newly diagnosed IDH-mutated gliomas in Germany. CONCLUSION: This study gives an overview of the incidence of WHO grade 2 and grade 3 gliomas among the German population. Furthermore, this study highlights the need of molecular information being integrated into epidemiologic monitoring of gliomas to obtain more precise insights into survival and prognostic factors.
引用
- Weidl D, Capper D, Onken J, et al. Epidemiology of WHO grade 2 and grade 3 gliomas from 2009 to 2021 in Germany. J Neurooncol. 2025. PMID: 40358804. doi:10.1007/s11060-025-05068-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。